From Wikipedia, the free encyclopedia
Jump to: navigation, search
Edoxaban skeletal.svg
Systematic (IUPAC) name
Clinical data
Trade names Lixiana, Savaysa
AHFS/Drugs.com Monograph
  • US: C
Pharmacokinetic data
Bioavailability 62%; Tmax 1–2 hours
Protein binding 55%
Metabolism Minimal hepatic
Half-life 10–14 hours
Excretion 50% renal; <50% bile
912273-65-5 YesY
PubChem CID 25022378
ChemSpider 8456212 N
KEGG D09710 N
Chemical data
Formula C24H30ClN7O4S
548.056 g/mol
 N (what is this?)  (verify)

Edoxaban (INN, codenamed DU-176b, trade names Savaysa, Lixiana) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery.[1] It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.[2]

Mechanism of Action[edit]

Edoxaban inhibits free factor Xa and prothrombinase activity and inhibits thrombin-induced platelet aggregation. Inhibition of factor Xa in the coagulation cascade reduces thrombin generation and thrombus formation.[3][4]

Factor Xa[edit]

Factor Xa (FXa) is an essential blood coagulation factor[5] that is responsible for the initiation of the coagulation cascade. FXa cleaves prothrombin to its active form thrombin, which then acts to convert soluble fibrinogen to insoluble fibrin and to activate platelets. Stabilization of the platelet aggregation by fibrin mesh ultimately leads to clot formation.[6]

Medical Uses[edit]

US FDA labeled Indications: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)

Limitations of use: Edoxaban should not be used in NVAF patients with CrCl >95 mL/minute because of an increased risk of ischemic stroke compared to warfarin[7]

Dosing and Formulations[edit]

Nonvalvular Atrial Fibrillation

The recommended dose of edoxaban is 60 mg taken orally once daily.

  • Do not use edoxaban in patients with CrCL > 95 mL/min.
  • Reduce edoxaban dose to 30 mg once daily in patients with CrCL 15 to 50 mL/min.

Deep Vein Thrombosis and Pulmonary Embolism

The recommended dose of edoxaban is 60 mg taken orally once daily following 5 to 10 days of initial therapy with a parenteral anticoagulant.

The recommended dose of edoxaban is 30 mg once daily in patients with CrCL 15 to 50 mL/min, patients who weigh less than or equal to 60 kg, or patients who are taking certain concomitant P-gp inhibitor medications based on clinical study data in this indication

3 formulations

  • 60 mg, yellow round shaped, film-coated tablets, debossed with DSC L60 on one side
  • 30 mg, pink round shaped, film-coated tablets, debossed with DSC L30 on one side
  • 15 mg, orange round shaped, film-coated tablets, debossed with DSC L15 on one side[4]

Warnings and Contraindications[edit]

[U.S. Boxed Warning]: Premature discontinuation of any oral anticoagulant, including edoxaban, in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for reasons other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant.[3]

[U.S. Boxed Warning]: Do not administer to nonvalvular atrial fibrillation (NVAF) patients with CrCl >95 mL/minute. In clinical trials, these patients had an increased rate of ischemic stroke with edoxaban 60 mg once daily compared to patients treated with warfarin; use another anticoagulant in these patients.[3]

[U.S. Boxed Warning]: Spinal or epidural hematomas resulting in long-term or permanent paralysis may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal/epidural puncture; the risk is increased by the use of indwelling epidural catheters, concomitant administration of other drugs that affect hemostasis (eg, NSAIDS, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, a history of spinal deformity or surgery, or if optimal timing between the administration of edoxaban and neuraxial procedures is not known. Consider the potential benefit versus risk prior to neuraxial intervention in patients who are anticoagulated or scheduled to be anticoagulated for thromboprophylaxis. Monitor frequently for signs and symptoms of neurologic impairment (eg, numbness/weakness of legs, bowel/bladder dysfunction). If neurologic impairment is noted, prompt treatment is necessary.[3]

Contraindicated in patients with active pathological bleeding.[4]

Adverse Effects[edit]

More common

  • bloody nose
  • heavy non-menstrual vaginal bleeding
  • pale skin
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Less common

  • bloody or black, tarry stools
  • vomiting of blood or material that looks like coffee grounds
  • rash


  • confusion
  • cough
  • difficulty with speaking
  • double vision
  • fever
  • headache, sudden, severe
  • inability to move the arms, legs, or facial muscles
  • inability to speak
  • nausea and vomiting
  • slow speech[8]

Clinical Trials[edit]

Several Phase II clinical trials have been conducted to assess the efficacy, safety and dose-response of edoxaban verses placebo and enoxaparin for thromboprophylaxis after total hip replacement[9] and total knee replacement (phase III early results compare well to enoxaparin[10]), as well as stroke prevention in patients with atrial fibrillation[11].

A large phase III trial (ENGAGE AF-TIMI)[12] showed that edoxaban was non inferior to warfarin in preventing recurrent venous thromboembolic events with fewer episodes of major bleeding.[13]

Researchers are currently recruiting subjects for the first Phase I trail in pediatric patients[14] as well as several other trials. A complete listing of completed and ongoing trials can be found at Clinicaltrials.gov.

Related Drugs[edit]

A number of anticoagulants inhibit the activity of Factor Xa. Unfractionated heparin (UFH), low molecular weight heparin (LMWH), and fondaparinux inhibit the activity of factor Xa indirectly by binding to circulating antithrombin (AT III). These agents must be injected. Warfarin, phenprocoumon, and acenocoumarol are orally active vitamin K antagonists (VKA) which decrease hepatic synthesis of a number of coagulation factors, including Factor X. In recent years, a new series of oral, direct acting inhibitors of Factor Xa have entered clinical development. These include rivaroxaban, apixaban, betrixaban, LY517717, darexaban (YM150), and edoxaban (DU-176b).[15]


  1. ^ "First market approval in Japan for LIXIANA (Edoxaban)". Press Release. Daiichi Sankyo Europe GmbH. 2011-04-22. 
  2. ^ O'Riordan, Michael (9 January 2015). "FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE Prevention". Medscape. Retrieved 10 January 2015. 
  3. ^ a b c d lexicomp.com
  4. ^ a b c Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo; January 2015.
  5. ^ Yoshiyuki, I., et al. "Biochemical and pharmalogical profile of darexaban, an oral direct Xa inhibitor." European Journal of Pharmacology (2011): 49-55
  6. ^ Katsung, B., S. Masters and A. Trevor. Basic and Clinical Pharmacology 11th Edition. United States of America: McGraw-Hill, 2009
  7. ^ http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf
  8. ^ http://www.drugs.com/cons/edoxaban.html
  9. ^ Raskob, G.; Cohen, A. T.; Eriksson, B. I.; Puskas, D.; Shi, M.; Bocanegra, T.; Weitz, J. I. (2010). "Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement". Thrombosis and Haemostasis 104 (3): 642–649. doi:10.1160/TH10-02-0142. PMID 20589317.  edit
  10. ^ "Phase III Trial Finds Edoxaban Outclasses Enoxaparin in Preventing Venous Thromboembolic Events". 8 Dec 2010. 
  11. ^ Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (September 2010). "Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation". Thromb. Haemost. 104 (3): 633–41. doi:10.1160/TH10-01-0066. PMID 20694273. 
  12. ^ Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)http://www.sciencedirect.com/science/article/pii/S0002870310005582
  13. ^ "Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism". N. Engl. J. Med. 369 (15): 1406–15. August 2013. doi:10.1056/NEJMoa1306638. PMID 23991658. 
  14. ^ https://clinicaltrials.gov/ct2/show/NCT02303431?term=edoxaban&rank=9
  15. ^ Turpie AG (January 2008). "New oral anticoagulants in atrial fibrillation". European Heart Journal 29 (2): 155–65. doi:10.1093/eurheartj/ehm575. PMID 18096568.